No Data
No Data
Novavax, Inc. (NVAX) Q2 2024 Earnings Call Transcript
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
Novavax Is a 'Super Volatile Stock,' Strategist Explains
Express News | Novavax Exec Says Expectations for Sales Performance in U.s Market in 2024 Remain Unchanged
Novavax Exec Says Updated COVID Vaccine Arriving In US Warehouse This Month, Distribution To Start After FDA Authorization; Expects More Successful US Vaccination Season Compared To Last Year; Data Indicates Vaccine Targeting JN.1 Should Provide...
Novavax Drops After Q2 Miss and Guidance Cut
No Data